30832741|t|Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
30832741|a|Pathological tau aggregates in Alzheimer's disease (AD) and frontotemporal lobar degeneration-tau (FTLD-tau) adopt distinct conformations differentiated by the AD-tau specific monoclonal antibody (mAb) GT-38 that are not readily visualized using phosphorylation-specific anti-tau mAbs. To determine the extent of co-morbid AD-tau pathology in FTLD-tau, we performed immunohistochemical (IHC) staining with GT-38 and assigned Braak stages of AD-tau in a cohort 180 FTLD-tau cases consisting of corticobasal degeneration (CBD; n = 49), progressive supranuclear palsy (PSP; n = 109), and Pick's disease (PiD; n = 22). Nearly two-thirds of patients (n = 115 of 180, 63.8%) with FTLD-tau had some degree of comorbid AD-tau pathology and 20.5% of the FTLD-tau cohort had Braak stage >=B2, consistent with medium-to-high-level AD neuropathological change (ADNPC). The PSP group had the highest frequency of medium-high AD-tau pathology compared to other tauopathies (PSP = 31/109, 28.4%; Picks = 2/22, 9.1%, CBD = 4/49, 8.2%) but neuropathological diagnosis was not found to be a significant independent predictor of medium-high AD Braak stage in a multivariate model after accounting for age at death (OR = 1.09; 95% CI = 1.03-1.15; p = 0.002) and CERAD plaque scores (OR = 3.75, 95% CI = 1.58-8.89; p = 0.003), suggesting there is no predilection for a specific FTLD tauopathy to develop AD-tau co-pathology after accounting for age. Patients with FTLD-tau who had, clinically significant, medium-high AD-tau pathology had significantly higher antemortem CSF levels of both total-tau (t-tau; mean = 89.98 pg/ml, SD = 36.70 pg/ml) and phosphorylated-tau (p-tau; mean = 20.45 pg/ml, SD = 9.31 pg/ml) compared to patients with negligible-low AD-tau, t-tau (mean = 43.04 pg/ml, SD = 25.40 pg/ml) and p-tau (mean = 11.90 pg/ml, SD = 4.48 pg/ml) (p <= 0.001 both). Finally, in an exploratory analysis in our largest pathology group (PSP) we find an association of GT-38 AD-tau Braak stage with lower baseline MMSE (p = 0.03). Together, these finding validate the use of GT-38 to selectively detect AD-tau pathology in the context of FTLD-tau and provides a novel tool to investigate associations of clinical phenotypes amongst co-morbid tauopathies.
30832741	13	32	Alzheimer's disease	Disease	MESH:D000544
30832741	34	36	AD	Disease	MESH:D000544
30832741	47	50	tau	Gene	4137
30832741	94	97	tau	Gene	4137
30832741	131	168	frontotemporal lobar degeneration-tau	Disease	MESH:D057174
30832741	170	178	FTLD-tau	Disease	MESH:D057174
30832741	194	197	tau	Gene	4137
30832741	212	231	Alzheimer's disease	Disease	MESH:D000544
30832741	233	235	AD	Disease	MESH:D000544
30832741	241	278	frontotemporal lobar degeneration-tau	Disease	MESH:D057174
30832741	280	288	FTLD-tau	Disease	MESH:D057174
30832741	341	347	AD-tau	Disease	MESH:C536599
30832741	383	388	GT-38	Chemical	-
30832741	457	460	tau	Gene	4137
30832741	504	510	AD-tau	Disease	MESH:C536599
30832741	524	532	FTLD-tau	Disease	MESH:D057174
30832741	587	592	GT-38	Chemical	-
30832741	622	628	AD-tau	Disease	MESH:C536599
30832741	645	653	FTLD-tau	Disease	MESH:D057174
30832741	674	699	corticobasal degeneration	Disease	MESH:D000088282
30832741	701	704	CBD	Disease	MESH:D000088282
30832741	715	745	progressive supranuclear palsy	Disease	MESH:D013494
30832741	747	750	PSP	Disease	MESH:D013494
30832741	766	780	Pick's disease	Disease	MESH:D020774
30832741	782	785	PiD	Disease	MESH:D020774
30832741	817	825	patients	Species	9606
30832741	855	863	FTLD-tau	Disease	MESH:D057174
30832741	892	898	AD-tau	Disease	MESH:C536599
30832741	926	934	FTLD-tau	Disease	MESH:D057174
30832741	1001	1028	AD neuropathological change	Disease	MESH:D000544
30832741	1030	1035	ADNPC	Disease	MESH:D000544
30832741	1042	1045	PSP	Disease	MESH:D013494
30832741	1093	1099	AD-tau	Disease	MESH:C536599
30832741	1128	1139	tauopathies	Disease	MESH:D024801
30832741	1141	1144	PSP	Disease	MESH:D013494
30832741	1162	1167	Picks	Disease	MESH:D020774
30832741	1182	1185	CBD	Disease	MESH:D000088282
30832741	1303	1305	AD	Disease	MESH:D000544
30832741	1370	1375	death	Disease	MESH:D003643
30832741	1538	1552	FTLD tauopathy	Disease	MESH:D024801
30832741	1564	1570	AD-tau	Disease	MESH:C536599
30832741	1610	1618	Patients	Species	9606
30832741	1624	1632	FTLD-tau	Disease	MESH:D057174
30832741	1678	1684	AD-tau	Disease	MESH:C536599
30832741	1756	1759	tau	Gene	4137
30832741	1825	1828	tau	Gene	4137
30832741	1886	1894	patients	Species	9606
30832741	1915	1921	AD-tau	Disease	MESH:C536599
30832741	2103	2106	PSP	Disease	MESH:D013494
30832741	2134	2139	GT-38	Chemical	-
30832741	2140	2146	AD-tau	Disease	MESH:C536599
30832741	2240	2245	GT-38	Chemical	-
30832741	2268	2274	AD-tau	Disease	MESH:C536599
30832741	2303	2311	FTLD-tau	Disease	MESH:D057174
30832741	2407	2418	tauopathies	Disease	MESH:D024801
30832741	Association	MESH:D057174	4137
30832741	Association	MESH:D000544	4137

